Sentences with phrase «cell replacement therapy in»

Diabetes Forecast highlighted ViaCyte's first - of - a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.

Our long - term goal, therefore, is to explore the potential to genetically disrupt both ccr5 and cxcr4 for cell replacement therapies in HIV infected individuals, and in the case of cxcr4 do so in a way that specifically targets CXCR4 on T cells and not the many other cell types on which it is expressed.

ViaCyte has two stem cell - based islet cell replacement therapies in clinical development.

Not exact matches

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

These cells, in turn, instruct factor - VIII — specific immune cells to become tolerant to the coagulation protein, resulting in suppression of misdirected antibody responses to the replacement therapy — all without affecting the rest of the immune system.

One potential treatment for CF is gene therapy, and a major challenge in gene therapy is packaging replacement genes so they can be delivered to the target cells.

But in patients with type 1 diabetes, beta - cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.

«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.

An EU - funded research project («HumEn»), in which Lickert and his team are participating, shall provide further insights in the field of beta - cell replacement therapy.

However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.

The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.

Regardless of the targeted organ for cell replacement or regeneration, the shared challenges in cell therapies for diabetes such as transplant procedure and immune rejection will be well - served by the collective expertise within CCTD.

ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.

In addition, ViaCyte launched the first clinical trials for stem cell - derived islet replacement therapies for type 1 diabetes.

The cells generated in the Zeng lab may not only provide a potential unlimited source for cell replacement therapy for Parkinson's disease, but also offer an unprecedented opportunity to develop screening models for assessing small molecule drugs and to clarify the mechanisms of disease.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

This information could then be used to prompt embryonic stem cells to differentiate in the culture dish into neurons for potential use in cell - replacement therapy.

Scientists publishing in the journal Cell Stem Cell have reported the production of functional human oocytes from discarded genetic material, a process which they suggest could one day assist in fertility treatment or mitochondrial replacement therapy.

This brings together the two leaders in cell replacement therapies for diabetes.

He is particularly interested in the mechanisms and molecules that regulate neural stem cell maintenance, cell fate programming and neural stem cell replacement therapies.

The title of the paper is «The Ideal Gene Delivery Vector: Chromallocytes, Cell Repair Nanorobots for Chromosome Replacement Therapy» and it is currently in press at the peer - reviewed Journal of Evolution and Technology (and is soon to be available online).

There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.

While many important developments impacted the field, two that garnered significant public, political and scientific attention in 2016 were the proliferation of clinics using unproven stem cell «therapies,» and the steps forward in therapeutic modification of human oocytes (unfertilized eggs) through a process called mitochondrial replacement therapy (MRT).

«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

In addition, we use our expertise to facilitate the development of functionally mature beta cells from embryonic stem cells for cell replacement therapies of type 1 diabetes.

Similarly, in the laboratory we've been studying cell replacement therapy.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.

The first - in - human STEP ONE * trial is evaluating the safety and efficacy of ViaCyte's PEC - Encap (a.k.a. VC - 01 ™) product candidate, a stem cell - derived, encapsulated cell replacement therapy.

STEP ONE is the first trial in the world investigating a stem cell - derived beta cell replacement therapy for diabetes.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

ViaCyte's VC - 01 ™ product candidate, a first - in - class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC - 01 Combination Product in Type One Diabetes.

Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem cell sources for the derivation of specific types of clinically relevant neuronal or glial cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future cell replacement - based therapy.

The initial phase of clinical investigation is focusing on the safety of the cell replacement therapy combination products in patients.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

Partial clinical hold on high dose SGT - 001 resolved, additional information requested on full clinical hold NIH grant will further development of replacement beta cells for type 1 and type 2 diabetes New trial will assess MSCs to improve heart function in heart failure patients ReNeuron wins grant for retinal cell therapy development

«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.

The VC - 01 product candidate is the first embryonic stem cell - derived islet replacement therapy to reach clinical testing and is currently being evaluated in patients with T1D who have minimal to no insulin - producing beta cell function.

Understanding how heart muscle cells, or cardiomyocytes, change in space improves efforts for studying disease, screening drugs and conducting cell replacement therapy for future space missions.

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

«In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell - derived cell replacement therapIn particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell - derived cell replacement therapin the field of stem cell - derived cell replacement therapy.

The author's goal with this insider's guide is to give readers the information needed to distinguish between the... View Details Stem Cell Revolution: Discover 26 Disruptive Technological Advances to Stem Cell Activation by Joseph Christiano (Author) Addressing chronic back pain, diabetes, joint replacements, osteoarthritis, neurological issues, and more, Joseph «Dr. Joe» Christiano reveals how this cutting - edge therapy can rapidly replace damaged cells in the body with no side effects or allergic reactions.

«You can manipulate stem cells and propagate them in a dish, but many recipients of stem cell replacement therapies will be older individuals.

ViaCyte's stem cell replacement therapy for the treatment of type 1 diabetes was highlighted in a June 2012 Popular Science article on artificial organs.

Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.

Importantly, because it is already approved for clinical use, amiodarone HCL may have clinical applications in cell replacement therapies by selectively removing only the unwanted undifferentiated NSCs during the pre-transplant period.